Ke Liu

Ke Liu

Auto-generated profile, based on publicly available information

Ke Liu

Tytgat Institute for Liver and Intestinal Research, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2025 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
QSQing Sha
Qing Sha
QYQiaoni Yu
Qiaoni Yu
KCKaixing Chen
Kaixing Chen
JWJunyu Wang
Junyu Wang
FWFeiyang Wang
Feiyang Wang
CGChuang Guo
Chuang Guo
The human decidua establishes immune tolerance at the maternal–fetal interface and is essential for successful embryo implantation and development. Here, we conducted a spatial transcriptomic analysis of human decidua from early pregnancies in both healthy donors and patients with recurrent pregnancy loss (RPL). Our analysis revealed two distinct spatial domains, named implantation zone (IZ) and glandular-secretory zone (GZ), corresponding to the layers of decidua compacta and spongiosa, respectively. The decidual natural killer cell subset (dNK1) and the decidual macrophage subset (dM2), both associated with growth promotion and immune regulation, were predominantly localized in the healthy IZ but were significantly reduced in RPL patients. In contrast, cytotoxic CD8+ T cells, sparsely distributed in the healthy decidual IZ and GZ domains, were elevated in both domains under RPL conditions. Spatial cell–cell interaction analysis indicated a broad exhibition but a marked downregulation of immunoregulatory interactions in the IZ of RPL patients. Through integrated single-cell chromatin accessibility and transcription factor occupancy analyses, we identified FOSL2 as a pivotal regulator orchestrating the spatial transformation of dNK1 cells. Decreased FOSL2 expression correlated with compromised IL-15-induced dNK1 cell transformation and diminished immunoregulatory capabilities. Our findings delineate the intricate spatial and regulatory architecture of immune tolerance within the human decidua, providing new insights into immune tolerance dysregulation in RPL.

8 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
IFIvan C.N. Fung
Ivan C.N. Fung
DJDjuna C. de Jong
Djuna C. de Jong
KLKe Liu
Ke Liu
AYAndrew Li Yim
Andrew Li Yim
SGSara van Gennep
Sara van Gennep
GDGeert R. D’HAens
Geert R. D’HAens
B ackground & O bjective: Tofacitinib, a Janus kinase (JAK) inhibitor, is approved for ulcerative colitis (UC). We investigated baseline and longitudinal transcriptomics and proteomics in intestinal biopsies, peripheral blood, and serum from UC patients starting tofacitinib to characterize treatment-associated effects and identify which molecular compartment harbors the most predictive response-associated biomarkers. M ethods: In this prospective, open-label study, patients with moderately to severely active UC started tofacitinib 10 mg BID for eight weeks. Clinical, biochemical, endoscopic, and histological data were collected at baseline and week 8. The primary outcome, histo-endoscopic mucosal improvement (HEMI), was defined as endoscopic Mayo subscore ≤1 with histologic remission (Robarts Histopathology Index ≤3, no mucosal neutrophils). Mucosal biopsies and peripheral blood were collected at baseline and week 8 for bulk RNA-sequencing (RNA-seq); biopsies and serum underwent proteomic profiling using Olink Explore 384 (Cardiometabolic, Inflammation, Neurology, Oncology panels). R esults: In total, 127 paired multi-omic samples were collected longitudinally from 40 UC patients: 15 (38%) achieved HEMI at week 8 (responders), 13 (32.5%) were late responders, and 12 (30%) were non-responders. Pretreatment mucosal biopsies from future responders showed elevated interferon, IL-6-family, IL-2/common-γ-chain, and T-cell-receptor signaling gene expression, which declined on treatment only in responders. A responder-specific JAK-STAT-dependent mechanism spanned interferon, cytokine-receptor, T-cell-receptor, and NF-κB signaling, with concordant gene- and protein-level reductions. Compared with a public infliximab dataset, JAK-STAT/interferon downregulation was shared and response-independent, while non-canonical NF-κB downregulation was tofacitinib-specific. In blood, shared pathway labels reflected distinct genes from mucosal effectors. C onclusion: Response to tofacitinib depends on a JAK-tractable mucosal pathway absent in non-responders, suggesting a pretreatment biomarker for predicting treatment response. What is already known on this topic: Prior studies have individually interrogated transcriptomic and/or epigenomic signatures of tofacitinib response as a single modality. What this study adds: Our study provides simultaneous profiling of both the transcriptome and proteome across paired mucosal and systemic compartments in patients, comparing responders with non-responders at baseline and over time. Our data support a model where tofacitinib response in UC depends on a JAK-dependent pro-inflammatory phenotype that the drug can dismantle, in contrast to non-responders representing distinct, JAK-independent pathways. How this study might affect research, practice or policy: This study provides a foundation for treatment response studies in UC towards the development and validation of predictive biomarkers in colonic mucosa and blood, which could ultimately result in more personalized treatment strategies.